D07001 + capecitabine

**D07001 + capecitabine** is an investigational oral fixed-dose combination comprised of D07001-softgel capsules (an absorption-enhanced oral formulation of gemcitabine) and capecitabine (an oral prodrug of 5-fluorouracil). D07001 allows for oral administration of gemcitabine, a nucleoside analog that interferes with DNA synthesis, while capecitabine is metabolized to 5-fluorouracil, exerting antimetabolite cytotoxic actions. This combination is being evaluated in phase III clinical trials for patients with advanced biliary tract cancer who have previously failed standard intravenous chemotherapy regimens. The combination aims to improve overall survival and offers a fully oral regimen for patients unable to continue with or unresponsive to prior therapies[1][3][5][9].

Brand names

Xeloda

Other names

capecitabineD07001-softgel capsulesD-07001-softgel capsulesD 07001-softgel capsules